YXYouwei Xu

Youwei Xu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Youwei Xu has a total of 259 co-authors. Here are the top co-authors by number of shared publications:

  • H. Eric Xu

    CAS Key Laboratory of Receptor Research, Center for Structure and Function of Drug Targets, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China

    33 shared publications
  • Qingning Yuan

    Research Center for Medicinal Structural Biology, National Research Center for Translational Medicine at Shanghai, State Key Laboratory of Medical Genomics, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

    18 shared publications
  • Kai Wu

    The State Key Laboratory of Drug Research, Center for Structure and Function of Drug Targets, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China

    15 shared publications
  • Wen Hu

    The State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China

    13 shared publications
  • Xinheng He

    The State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China

    13 shared publications
  • Yi Jiang

    School of Life Science and Technology, ShanghaiTech University, Shanghai, China

    12 shared publications

Latest Publications

  • Multiple allosteric sites allow for synergistic enhancement of GPCR signaling

    by Kai Wang, Snezana T. Dimova, John N. Hanson, Abhishek Thakur, Youwei Xu, Yini Liu, Amy E. Moritz, Alexander Goldberg, Bing Xie, Jayachandra Rayadurgam, et al.

    Allosteric modulation of G protein–coupled receptors (GPCRs) offers promising therapeutic opportunities. Although multiple allosteric binding sites have been identified in GPCRs, whether and how these spatially distinct sites cooperate to regulate receptor activation remain poorly understood. Here, we elucidate the molecular mechanism of cooperative multisite allostery in the dopamine D1 receptor (D1R). We developed two novel D1R positive allosteric modulators (PAMs), UNC9815 and UNC10062, and used cryo–electron microscopy to structurally identify two previously uncharacterized D1R allosteric sites occupied by UNC9815/UNC10062 and another D1R PAM, BMS-A1. Both sites localize to the transmembrane helix (TM) 1 to 7 interface as vertically adjacent allosteric pockets organized in a spatially complementary manner. Our structures demonstrate the simultaneous binding of the chemically distinct PAMs (LY3154207, BMS-A1, and UNC9815/UNC10062) in three nonoverlapping pockets. Concurrent engagement of all three allosteric sites produces pronounced functional cooperativity, increasing dopamine potency by >1000-fold, thereby demonstrating that coordinated multisite modulation can achieve substantial pharmacological amplification beyond the limits imposed by single PAM administration. Molecular dynamics (MD) simulations revealed that multisite PAM engagement restricts intracellular loop 3 dynamics and stabilizes the TM7-NPxxY activation motif, effects not achieved by binding of LY3154207 alone, thereby biasing the receptor toward a more stabilized active conformation, and may also improve agonist potency by stabilizing extracellular loop 2. Together, these findings establish the structural framework for cooperative multisite allostery in a GPCR, revealing how distributed allosteric sites act in concert to amplify receptor activation and providing a conceptual foundation for developing innovative GPCR allosteric therapeutics.

  • Open Access

    Lipid-organized tetramerization of PLPP1 defines the molecular basis of spatial lipid phosphate signaling

    by Yunhai Li, Qingning Yuan, Zhenyu Cao, Liuqing Zhu, Jiuyin Xu, Cheng-Cen Guo, James Jiqi Wang, Youwei Xu, Shuai Li, Tianyu Li, et al.

    Bioactive lipid phosphates, such as lysophosphatidic acid (LPA) and sphingosine-1-phosphate, are potent membrane-embedded signals that regulate fundamental processes in development, immunity, and cancer. The termination of these signals is mediated by phospholipid phosphatases (PLPPs), yet the molecular principles governing their function at the membrane interface have remained poorly understood. Here we report high-resolution cryo-electron microscopy structures of human PLPP1 in apo (1.87 Å) and product-bound (2.21 Å) states. The structures reveal a highly ordered, C4-symmetric homotetramer with ordered lipid densities—including densities assigned to phosphatidylcholine, phosphatidic acid, and phosphatidylinositol-4,5-bisphosphate—at inter-subunit interfaces. Structure-guided mutagenesis shows that residues surrounding these interfacial lipid densities affect enzymatic activity, whereas oligomerization analysis indicates that activity loss does not simply correlate with tetramer disruption. The product-bound structure defines the catalytic pocket and a membrane-facing tunnel that suggests a possible route for LPA access, while electrophysiological recordings detected no PLPP1-associated ion conductance under the conditions tested. Together, these findings provide a structural framework for PLPP1 tetramer assembly, lipid phosphate hydrolysis, and product recognition.

  • Cross-ribbon conformation defines peptide recognition in SCREW/CTNIP–NUT/HSL3 signalling

    by Xiaobin Wei, Mengyi Yao, Pingping Zhao, Xin Zhang, Kai Zhang, Wen Hu, Jiaqing Shi, Shuangyu Guo, Ruxin Li, Wei Wang, et al.

    Plants balance gas exchange with pathogen defense through dynamic stomatal regulation. Stomata close temporarily during pathogen attack to limit invasion, then reopen to restore photosynthesis and transpiration while lowering apoplast water saturation to inhibit pathogen proliferation. The secreted peptides, SCREW/CTNIP promote stomatal reopening through the receptor NUT/HSL3 and co-receptor BAK1/SERK3, thereby counteracting ABA and MAMP-triggered stomatal closure. Here we present the cryo-EM structures of AtNUTECD and the AtNUTECD–SCREW2/CTNIP4–AtBAK1ECD complex, uncovering a distinctive peptide–receptor interaction mechanism. SCREW2 adopts a unique cross-ribbon conformation that distinguishes it from other known conformations of LRR-RK-binding peptides, enabling its specific recognition by AtNUT and subsequent recruitment of AtBAK1. An N-linked glycan at N449 within the SCREW2–AtNUT binding interface is required for efficient SCREW2 recognition. Mutations in SCREW2 recognition sites significantly attenuated downstream MAPK activation and PTI marker gene expression.


  • Primate-specific regulation of the human glycosphingolipid gatekeeper UGCG

    by Canrong Wu, Sanshan Jin, Jiuyin Xu, James Jiqi Wang, Xiaoqi Guo, Yunhai Li, Zhenyu Cao, Mengting Jiang, Qingning Yuan, Wen Hu, et al.


  • Open Access

    Structural basis for a central permeation pathway in the P2X1 receptor

    by Heng Zhang, Pengpeng Wu, Zhiyong Gu, Youwei Xu, Wen Hu, Qingning Yuan, Bingqing Xia, H. Eric Xu, Zhaobing Gao

    The ion permeation pathway is a critical determinant of ion channel function and selectivity; however, the structural basis for ion permeation in the P2X1 receptor, an ATP-gated ion channel crucial for platelet activation, thrombosis, and male infertility, remains incompletely understood. Here, we present high-resolution cryo-electron microscopy (cryo-EM) structures of the P2X1 receptor, which reveal a central ion permeation pathway spanning the entire extracellular domain, complementing the existing paradigms of ion channel architecture for the P2X receptor family. Within this pathway, we identify specific sites that coordinate hydrated calcium ions, including an aspartate ring that acts as a selectivity filter at the apex of the central vestibule. We also discover that a small molecule, 3,5-bis(trifluoromethyl)aniline, binds at the top of the central vestibule and potently inhibits cation flux through this central permeation pathway. Our findings reveal a new inhibitor-binding site in the P2X1 receptor. These insights provide a structural framework for the rational design of subtype-specific P2X receptor inhibitors targeting the central vestibule.

  • Open Access

    Rational design of a Kappa opioid receptor peptide agonist with attenuated β-arrestin signaling

    by Huanhuan Zhang, Ruolan Wang, Pan Shi, Gaoming Wang, Qingjun Zhu, Xinheng He, Youwei Xu, Qingning Yuan, Wen Hu, Kai Wu, et al.

    Difelikefalin is an FDA-approved κ-opioid receptor (KOR) peptide agonist used to treat chronic pruritus. However, as a balanced agonist that activates both G protein and β-arrestin pathways, difelikefalin remains associated with undesirable side effects linked to β-arrestin signaling. Here, we report the cryo-EM structure of the difelikefalin-KOR-Gi complex, identifying Y320 7.43 as a key residue that is critical for signaling bias. Guided by this structural insight, we engineer beta01, a β-amino acid-substituted analog with potent G protein activation but minimal β-arrestin recruitment. In mouse models, beta01 retains robust antinociceptive and antipruritic efficacy while significantly reducing sedation and anxiety-like behaviors. Structural, molecular dynamics simulations and 2D 13 C-Met NMR analyses further reveal beta01 stabilizes a unique KOR conformation with an expanded intracellular cavity that disfavors β-arrestin binding. This work establishes a rational structure-based framework for designing safer and more effective GPCR-targeted therapeutics.


  • Open Access

    Author Correction: Structural insights into antagonist recognition by the vasopressin V2 receptor

    by Tianwei Zhang, Hongli Liu, Chongzhao You, Yixiao Zhang, Youwei Xu, Benxun Pan, Canrong Wu, Sanshan Jin, Yu-Ling Yin, Kai Wu, et al.

  • Top Cited Papers
    Open Access

    Structure-based design of an opioid receptor modulator for enhanced morphine analgesia

    by Yue Wang, Ping Luo, Haiyan Xu, Li Zhan, Kensuke Sakamoto, Mingyu Li, Jing Wang, Xi-Ping Huang, Jianhui Zhou, Tao Liu, et al.

    The alarming rates of deaths due to opioid overdose present an urgent need for safer opioid analgesics. Positive allosteric modulators (PAMs) of opioid receptors (ORs) offer a promising approach to enhance opioid efficacy while reducing risks of overdose. In this study, we unveil the selective mechanism of PAM modulation of the OR family through structure elucidation of the δ-opioid receptor and μ-opioid receptor (μOR) bound to orthosteric agonists and PAMs BMS986187 (BMS187) and BMS986122 (BMS122). In addition, we uncovered an unexpected but conserved allosteric site across the transmembrane helices TM2 to TM4 of ORs, occupied by BMS187 but not BMS122. Leveraging these structural insights, we designed 9-(5-(4-chlorophenyl)furan-2-yl)-3,3,6,6-tetramethyl-3,4,5,6,7,9-hexahydro-1 H -xanthene-1,8(2 H )-dione (MPAM-15), whose αβ cooperativity factor is 33-fold higher than BMS122 and threefold higher than BMS187, indicating markedly stronger positive allosterism. Animal studies demonstrate that MPAM-15 shows excellent brain penetration and enhances morphine-induced antinociception without exacerbating respiratory depression or constipation. Molecular dynamics simulations revealed that MPAM-15 promotes and stabilizes the conformational equilibrium of μOR toward the canonical active state, providing a mechanistic basis for its enhanced allosteric potency. These discoveries substantially advance our understanding of OR allosteric mechanism and pave the way for the structure-based development of allosteric opioid analgesics.


  • Open Access

    Structural insights into antagonist recognition by the vasopressin V2 receptor

    by Tianwei Zhang, Hongli Liu, Chongzhao You, Yixiao Zhang, Youwei Xu, Benxun Pan, Canrong Wu, Sanshan Jin, Yu-Ling Yin, Kai Wu, et al.

    The vasopressin V2 receptor (V2R), a class A G protein-coupled receptor, is essential for regulating body water homeostasis. V2R antagonists have emerged as promising treatments for hyponatremia; however, the absence of structural information for antagonist-bound V2R hampers our understanding of antagonist recognition and the targeted design of V2R antagonists. In this study, we present two cryo-electron microscopy structures of inactive V2R bound to the clinically approved antagonists tolvaptan and conivaptan. Combined with functional analyses and molecular dynamic simulations, these structures reveal distinct binding poses: tolvaptan is deeply inserted within the binding pocket, whereas conivaptan is positioned at a shallower depth. Integrated analyses further define critical pharmacophoric features governing antagonist activity and unveil a TM7 helical conformation-dependent antagonism mechanism that is distinct from classical GPCR inactivation modes. Our findings deepen understanding of antagonist recognition and antagonism of V2R, providing a foundation for the development of V2R-targeted therapies.


  • Open Access

    Divergent activation patterns of BRS3 revealed by two Chinese herb-derived agonists

    by Jie Li, Changyao Li, Qingtong Zhou, Wei Han, Mingzhu Fang, Youwei Xu, Yiting Mai, Yao Zhang, Jiahua Cui, H. Eric Xu, et al.